Regeneron Announces Positive Phase 3 Trial for Garetosmab that prevents Greater than 99% abnormal bone formation

Dualitas Launches With $65 Million Series A to Advance Novel Bispecific Antibody Pipeline in Immune and Inflammatory Disease

ARTHEx Biotech Secures $87M for Myotonic Dystrophy Drug

Synthesize Bio Secures $10M to Pioneer Generative Genomics

Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label

Raludotatug Deruxtecan Receives FDA Breakthrough Therapy Status for Platinum-Resistant Ovarian Cancer

Corstasis Therapeutics Receives FDA Approval for Edema Drug ENBUMYST™

Enhanced Genomics extends Series A funding to USD $19 million to drive development of therapeutics pipeline

Lila Sciences Raises $235 Million Series A to Build Scientific Superintelligence

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases

Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement

YolTech Therapeutics Raises $45 Million in Series B Financing Led by AstraZeneca-CICC

Dewpoint Therapeutics Secures Series D Funding for Gastric Cancer Drug

Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD

Sapio Sciences and Ultima Genomics Partner to Advance Multi-Omics Research

Johnson & Johnson announces FDA approval of INLEXZO™ (gemcitabine intravesical system) to treat bladder cancers

Odyssey Therapeutics Announces $213 Million Series D Financing to Advance Clinical Pipeline for Autoimmune Diseases

Remedium Bio Announces Strategic Collaboration with Lilly to Develop Gene Therapies for Obesity and Type 2 Diabetes

Promega and Watchmaker Genomics Announce Strategic Partnership to Advance Molecular Analysis with Next-Generation Reverse Transcriptase

NRG Therapeutics Announces $67million Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND

Pulse Biosciences Receives FDA Approval to Begin Atrial Fibrillation Study

Congruence Therapeutics Raised $32M to Advance CGX-926 in Genetic Obesity

Servier Acquires KER-0193 from Kaerus Bioscience for Potential Fragile X Syndrome Treatment

Treeline Announces First Clinical Trials and Secures $200M in Additional Funding

Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers

Lupin's First Nanomi Long-Acting Injectable Product, Risperidone, Receives U.S. FDA Approval for Schizophrenia and Bipolar I Disorder

FDA Approves Henlius and Organon’s BILDYOS® and BILPREVDA®, Biosimilars to PROLIA and XGEVA Respectively for osteoporosis

CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML

Amgen to Build $500M+ Science Hub

Encoded Therapeutics Receives Key FDA Designation for Dravet Syndrome

Neucore Bio Awarded NIH STTR Phase I Grant to Pursue Exosome-based Genetic Medicine for CMT1A disease

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

SeqOne acquires Congenica to create a global leader in AI-powered genomic medicine

Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer

Moderna Receives FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2

Teva Announces FDA Approval of Generic Saxenda® – First Generic GLP-1 Indicated for Weight Loss

Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis

AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder

HERTHENA-Breast04: Patritumab Deruxtecan Trial for Metastatic HR+/HER2- Breast Cancer

Human Longevity Taps Alamar Biosciences to Power Proteomic Innovation in Longevity Research

Coya Therapeutics Gains FDA Go-Ahead to Begin ALS Trial with COYA 302

Innovent Biologics Receives FDA Approval for Squamous Non-Small Cell Lung Cancer Drug Study

MannKind Acquires scPharmaceuticals for Growth in Cardiometabolic and Lung Diseases

Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million

Kite to Acquire Interius BioTherapeutics for $350 million to Advance In Vivo Platform

DAWNZERA™ approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

BioSkryb Genomics Obtains Exclusive Patent for Single-Cell Methylation Mapping

Larkspur Biosciences Discovers New Colorectal Cancer Drug

Novocure Files for FDA Approval for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

Agilent MMR IHC Panel pharmDx Receives FDA Approval as a Companion Diagnostic Test for Colorectal Cancer

Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Small Cell Lung Cancer

VantAI and Halda Therapeutics Forge $1 Billion Alliance to Pioneer AI-Driven Proximity Therapies for Cancer and Immunology

Kelonia Begins Phase 1 CAR T-cell Therapy Study for Multiple Myeloma

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease

Skyhawk & Merck KGaA Partner to Discover Novel RNA-Targeting Small Molecules for Neurological Disorders

Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Iovance’s Amtagvi® (lifileucel) Receives Approval for Advanced Melanoma

ONWARD Medical Receives FDA Approval for Empower BP Study

FDA Grants Priority Review for Chimerix's New Drug for Recurrent H3 K27M-Mutant Diffuse Glioma

Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease

Syncell Forms Strategic Partnership with Thermo Fisher Scientific to Advance Spatial Proteomics

Trinity Biotech Receives FDA Approval to Launch PreClara™ Preeclampsia Test

Novo Nordisk's Wegovy® Receives First-of-its-Kind FDA Approval for MASH

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ for the Treatment of Fibromyalgia

FDA Approves PAPZIMEOS for Recurrent Respiratory Papillomatosis

Superluminal Joins Forces with Eli Lilly for Cardiometabolic Therapies

Avista Teams Up with Forge Biologics for AAV Development

Camena Bioscience and Constructive Bio partner to advance plant genomics

Aquestive Therapeutics Raises $85 Million to Fund Anaphylm™ Launch

FDA grants Regenerative Medicine Advanced Therapy Designation to Beam's BEAM-101 for Sickle Cell Disease

Tevogen.AI, Databricks, and Microsoft Collaborate on PredicTcell™ Model with focus on oncology

Apertura Licenses Blood-Brain Barrier Gene Therapy for CNS Treatments

PharmaTher Announces FDA Approval of KETARx™ for use in surgical pain management

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis

Viatris's FDA Approval of Generic Iron Sucrose Addresses Chronic Kidney Disease and Anemia

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

Arvinas Announces FDA Review of Vepdegestrant for ESR1m, ER+/HER2- Breast Cancer

Neucore Bio Secures NSF Grant to Scale Exosome-Based Therapies for Genetic Diseases

Beyond Protein Folding: Tahoe Therapeutics Fuels the "Virtual Cell" Revolution with $30M

Thermo Fisher Receives FDA Approval for NGS-Based Companion Diagnostic for New Non-Small Cell Lung Cancer Treatment

SOPHiA GENETICS and AstraZeneca Expand AI Partnership for Breast Cancer

10x Genomics to Acquire Scale Biosciences

Melinta Therapeutics announces its strategic acquisition by CorMedix

Pleno Inc. and Slopes Bio partner for large-scale RAPTOR instrument use

FDA approves Jazz Pharmaceuticals' Modeyso™ as first treatment for H3 K27M-mutant Diffuse Midline Glioma

First oral targeted therapy for HER2-mutant non-small cell lung cancer gets FDA approval

Chai Discovery Raises $70 Million to Revolutionize Molecular Design

$153M Series B Propels Strand Therapeutics' Programmable mRNA Pipeline

LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia

Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma

Exact Sciences and Humana Partner on Cologuard Plus™ for Colorectal Cancer Screening

Azenta Partners with Frenova and Nephronomics to Advance Kidney Research

Illumina enhances flagship assay to accelerate access to comprehensive tumor profiling

Ultromics Lands $55M Series C to Tackle Undiagnosed Heart Failure at Scale

Arbor Biotechnologies Doses First Patient in Landmark Gene Editing Trial for PH1

Calidi Biotherapeutics Gets FDA Fast Track for Novel Sarcoma Therapy CLD-201

United Therapeutics Fuels Growth with Record Revenue Amidst Key Pipeline Advancements

LTZ Therapeutics Teams Up with Eli Lilly to Accelerate Autoimmune Disease Platform

MapLight Therapeutics Announces $372.5 Million Series D Financing

Sephience™ by PTC Therapeutics Gets FDA Nod for PKU Treatment

Sarepta to Resume ELEVIDYS Shipments for Ambulatory Duchenne Patients After FDA Recommendation

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

Matchpoint Therapeutics Partners with Novartis to Develop Oral Anti-Inflammatory Drugs

Kling Bio and Sanofi Partner to Accelerate Neutralizing Antibody Discovery

IMBRUVICA® Becomes First Targeted Therapy Approved in EU for Untreated Transplant-Eligible Mantle Cell Lymphoma

Lupin Secures US FDA Approvals for Key Injectables

Solid Biosciences' SGT-501 Receives FDA Fast Track for CPVT Gene Therapy

Minimally Invasive Blood Test for Alzheimer's: Roche's Elecsys pTau181 Gets CE Mark

BullFrog AI's bfLEAP™: A New Blueprint for Smarter Drug Development

PhoreMost Unveils Systematic Approach to Molecular Glue Drug Discovery

Sarepta Suspends ELEVIDYS Shipments in U.S.

EU Approves Autolus' AUCATZYL® CAR T for Relapsed/Refractory B-ALL

Monte Rosa Doses First Patients in Phase 1 MRT-8102 Study for Inflammatory Diseases

J&J Seeks FDA Approval for Icotrokinra as a once daily pill in Plaque Psoriasis

Korro's KRRO-110 Garners EMA Orphan Drug Status to treat Alpha-1 Antitrypsin Deficiency

10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery

Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease

IDT Announces Translational CRISPR Portfolio Expansion with Product Innovation Updates

FDA Approves Biocon Biologics' Kirsty™: The First Interchangeable Rapid-Acting Insulin Aspart in the U.S.

AAVantgarde's AAVB-039 for Stargardt Disease Gains FDA Investigational New Drug Clearance

FDA Approves Updated Label for Kisunla, Featuring New Dosing to Significantly Reduce ARIA-E Risk in Alzheimer's

Moderna's Spikevax Gains FDA Approval for Vulnerable Children Aged 6 Months to 11 Years

MiNK Therapeutics' Allogeneic iNKT Cell Therapy Achieves Complete Remission in Metastatic Testicular Cancer

Synfini Secures $8.9M in Funding to Accelerate AI-Driven Small Molecule Drug Discovery

AbbVie and IGI Partner on ISB 2001: A Novel Trispecific Antibody for Relapsed/Refractory Multiple Myeloma

Recursion Takes Full Control of REV102: Accelerating AI-Driven Oral Therapy for Hypophosphatasia

MAIA Biotechnology Doses First Patient in Expanded Phase 2 Trial for Ateganosine in NSCLC

Miraterra acquires Trace Genomics, an Ag-tech company to unlock measurement and insights across soil, plants, and food

Myrtelle Begins Commercial Production of Gene Therapy for Canavan Disease

EMA Grants Nurix Therapeutics' Bexobrutideg (NX-5948) Orphan Drug Designation for Waldenström Macroglobulinemia

Hope for Rare Brain Cancers: MB-101 (CAR T-cells) from Mustang Bio Gains Orphan Drug Status for Astrocytomas and Glioblastoma

FDA Approves KalVista's EKTERLY®: The First Oral On-Demand Treatment for Hereditary Angioedema

FDA Grants Breakthrough Therapy Status to Lexeo Therapeutics' LX2006 for Friedreich Ataxia

ZEGFROVY® Gains FDA Accelerated Approval for NSCLC with EGFR Exon 20 Insertion Mutations with Thermo Fisher's Oncomine™ Dx as companion diagnostic test

FDA Accelerates Approval of Regeneron's Lynozyfic™ (linvoseltamab-gcpt) for Relapsed/Refractory Multiple Myeloma

AbbVie to Acquire Capstan Therapeutics to Transform Patient Care in Immunology

Clinical Development of ARGX-119 for Congenital Myasthenic Syndromes Accelerated by argenx

Plus Therapeutics Gains FDA Agreement for REYOBIQ™ Trial in Leptomeningeal Metastases

XtalPi and Pfizer Deepen Partnership for AI-Powered Drug Discovery

FDA Approves Gamifant: A Groundbreaking Treatment for Macrophage Activation Syndrome in Still's Disease

FDA Approves Takeda's GAMMAGARD LIQUID ERC: A Unique, Low IgA Immunoglobulin Therapy for Easier Patient Use

Push to Advance Cardiac RNA Therapeutics as Lexeo, Perceptive Xontogeny, and venBio Partner Up

Novartis Completes Acquisition of Regulus Therapeutics, Bolstering Renal Disease Pipeline

Evotec Leverages Multi-Omics in NURTuRE-AKI Collaboration to Combat Acute Kidney Injury